Human papillomavirus 6 (HPV6) is a low-risk type of human papillomavirus associated with benign epithelial proliferations such as anogenital warts and respiratory papillomatosis. It is a circular double‑stranded DNA virus belonging to the Papillomaviridae family and infects squamous cells of mucosal and cutaneous surfaces.
Biology and Clinical Features
Human Papillomavirus 6 belongs to the low‑risk alpha papillomaviruses. Its genome is a circular, double‑stranded DNA molecule of around 8 kb encoding early proteins that regulate replication and late proteins that form the viral capsid. The virus infects the basal layer of stratified squamous epithelium through small abrasions and establishes episomal persistence. Viral gene expression is linked to epithelial differentiation: early proteins drive replication in basal cells and late genes are expressed in the superficial layers to assemble virions. E6 and E7 proteins of HPV6 have low affinity for the tumour suppressors p53 and retinoblastoma protein, so lesions remain benign and progression to cancer is rare. Most infections are cleared by the host immune response within two years, but persistent infection can occur, especially in individuals with immunosuppression. HPV6 does not integrate into the host genome and remains episomal, which partly explains its low oncogenic potential. Infection induces acanthosis and hyperkeratosis and has a long incubation period. Innate and adaptive immune responses, particularly cell‑mediated immunity, are critical for clearance, although the virus can evade immunity by downregulating interferon signalling and antigen presentation. Transmission occurs through sexual contact or vertical transfer during birth. The quadrivalent and nonavalent HPV vaccines include HPV6 and target the L1 capsid protein to induce neutralising antibodies.
Clinical Manifestations and Prevention
HPV6 accounts for more than 90 % of anogenital warts along with HPV11. These lesions, also called condylomata acuminata, present as cauliflower‑like growths on the vulva, penis, perineum or perianal skin and mucosa. They can be flat or pedunculated and are managed with topical agents such as podophyllotoxin and imiquimod, cryotherapy or surgical removal. Recurrent respiratory papillomatosis is another condition in which HPV6 infects the laryngeal epithelium and leads to benign airway papillomas, causing hoarseness and respiratory obstruction. In children, vertical transmission from an infected mother during vaginal delivery is the main route. In the cervix, HPV6 may cause low‑grade squamous intraepithelial lesions detected by cytology, but progression to high‑grade dysplasia or carcinoma is uncommon. Prophylactic vaccines containing HPV6 reduce the incidence of genital warts. Using condoms and limiting sexual partners also decreases transmission, though barrier methods do not completely prevent infection because the virus can infect skin not covered by condoms. HPV6 is a common low‑risk papillomavirus that infects mucosal epithelium and causes benign lesions such as genital warts and respiratory papillomatosis. Its limited oncogenic potential reflects the weak transforming activity of its E6 and E7 proteins and its episomal replication. Vaccination, treatment of warts and safe sexual practices help control the spread of HPV6. Related Terms: Papillomaviridae, Anogenital warts, Low-risk HPV, Gardasil, HPV11